https://scholars.lib.ntu.edu.tw/handle/123456789/522998
標題: | A 12-year ecological study of hip fracture rates among older Taiwanese adults | 作者: | DING-CHENG CHAN Lee Y.-S. Wu Y.-J. Tsou H.-H. Chen C.-T. Hwang J.-S. KEH-SUNG TSAI RONG-SEN YANG |
公開日期: | 2013 | 卷: | 93 | 期: | 5 | 起(迄)頁: | 397-404 | 來源出版物: | Calcified Tissue International | 摘要: | Hip fracture rates in Taiwan are among the highest in the world. The aim of this study was to describe the trends of hip fracture hospitalizations among Taiwanese elderly (aged ? 65 years) and the trends of antiosteoporosis medication expenditure from 1999 to 2010. We conducted an ecological study using inpatient health care-utilization data from the Department of Health, and medication expenditure data from the IMS Health, Taiwan. The International Classification of Disease, Clinical Modification, 9th version, code 820 was used to identify hip fracture hospitalizations. Medications included alendronate, calcitonin, ibandronate, raloxifene, strontium ranelate, teriparatide, and zoledronic acid. Year 2010 was assigned as the reference point for age-standardized rates, currency exchange (to the US dollar), and discount rates. Over the 12-year study period, age-standardized hip fracture hospitalizations decreased by 2.7 % annually (p for trend < 0.001) for Taiwanese elders. The decline was more obvious among those aged ?75 years (6.1 %). However, the number of hip fracture hospitalizations increased from 14,342 to 18,023. Total hospitalization costs increased by US$0.6 ± 0.2 million annually (p for trend = 0.002); however, the per capita costs decreased by US$23.0 ± 8.0 (p for trend = 0.017). The total medication expenditure increased 7.2-fold, from US$8.1 million to US$58.9 million, accounting for an increase in the overall pharmaceutical market by fivefold, from 3.4 to 15.9 ? (both p for trend < 0.001). From 1999 to 2010, there was a decline in hip fracture rates among elderly Taiwanese adults with a concomitant increase in antiosteoporosis medication expenditure. ? 2013 Springer Science+Business Media New York. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84886410542&doi=10.1007%2fs00223-013-9759-x&partnerID=40&md5=1ae97432678d06cc21f0e530d5bc36c1 https://scholars.lib.ntu.edu.tw/handle/123456789/522998 |
ISSN: | 0171-967X | DOI: | 10.1007/s00223-013-9759-x | SDG/關鍵字: | alendronic acid; calcitonin; ibandronic acid; parathyroid hormone[1-34]; raloxifene; strontium ranelate; zoledronic acid; age distribution; aged; aged hospital patient; article; controlled study; drug cost; ethnic group; health care utilization; hip fracture; hospitalization cost; human; ICD-9-CM; major clinical study; priority journal; Taiwanese; trend study; Aged; Aged, 80 and over; Bone Density Conservation Agents; Female; Health Expenditures; Hip Fractures; Hospitalization; Humans; Longitudinal Studies; Male; Osteoporosis; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。